Navigation Links
Despite Oncologists' Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
Date:2/11/2008

Seventy-nine Percent of U.S. Oncologists Currently Use Avastin to Treat the

Disease, According to a New Macroview Update from Decision Resources

WALTHAM, Mass., Feb. 11 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, reports that the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against Genentech/Roche's Avastin for first-line treatment of breast cancer in December 2007. According to the new Macroview update, the FDA's ODAC voted 5 to 4 that data are insufficient to recommend Avastin for approval for first-line treatment of metastatic or recurrent breast cancer.

The ODAC said that in the absence of a benefit in overall survival, Avastin's 5.5 month improvement in progression-free survival does not outweigh the risks associated with the drug.

An August 2007 survey by Decision Resources found that a very high rate of oncologists prescribing Avastin off-label to treat metastatic breast cancer.

"In August of 2007, 79 percent of U.S. oncologists were using Avastin to treat breast cancer patients," said Mary Fletcher-Louis., director at Decision Resources. "This prescribing behavior is driven by familiarity with Avastin for colorectal cancer and non-small-cell lung cancer, and by approval of this agent for breast cancer in Europe."

The FDA is not bound by the ODAC vote, and will make its final decision by February 23, 2008. For commentary on the final vote, please contact Elizabeth Marshall at 781-296-2563 to schedule an interview with Dr. Argent-Katwala.

About Macroview from Decision Resources

Macroview is the most up-to-date analysis on events impacting the healthcare industry. The Macroview updates are part of Decision Resources' Pharmaview product line, which offers a thorough analysis of the biopharmaceutical sector from a therapy, industry and company point-of-view.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Despite polarized opinions, Democrats and Republicans perform same amount of green actions
2. Physicians Still Hopeful About Desmoteplase for the Treatment of Acute Ischemic Stroke Despite Negative Results
3. Herons persist in Chicago wetlands despite exposure to banned chemicals
4. Despite efforts, significant racial disparities in cancer therapy still exist
5. Coshocton County Memorial Hospital RNs to Strike Despite Hospitals Claim of Financial Hardship
6. Miscarriage myths persist despite prevalence of medical information
7. Research finds allergic children exposed to peanuts at younger ages despite recommendations to avoid
8. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
9. A Full and Long Life, Despite Diabetes
10. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
11. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology: